Septest.

Pioneering rapid infection and inflammation diagnostics.

In the Spotlight

Septest shortlisted for Medilink Startup Award.

Septest has been shortlisted in the startup category at the Medilink Healthcare Business Awards 2024.

This category highlights the efforts of newly established companies in the healthcare sector that show a promising future.

Septest wins the TBAT Innovation Challenge.

Septest has won the TBAT innovation challenge. Septest not only secured the judges vote but also won the audience winner vote.

Co-founder Kelly pitched at the packed showcase event alongside the nine other finalists to claim the top prize package provided by TBAT and its industry partners worth over £50,000.

Septest Completes Herts Healthcare Accelerator.

Septest has completed the 2023 hearts healthcare accelerator.

The programme provided access to a range of experts from across various fields including life sciences, technology, design, business, and law to enable the development of innovations and early stage research.

About Us

Septest was born from a deep personal experience. Founded by a sepsis survivor, we understand firsthand the critical need for rapid and accurate infection diagnostics.

Our mission is to transform how infections are detected and managed, ultimately saving lives and improving patient outcomes.
At Septest, we are committed to developing groundbreaking diagnostic tools that offer clarity and speed in identifying infections and inflammation. We aim to empower healthcare professionals with the information they need to provide timely, effective care, particularly in the fight against sepsis and antimicrobial resistance (AMR).

Spotlight on Sepsis

Sepsis is a life-threatening illness caused by the body's response to an infection, resulting in systemic inflammation and organ dysfunction. It can affect anybody, from infants to the elderly, and progresses rapidly if not diagnosed and treated promptly.

Recognised as a global health crisis, sepsis affects an estimated 48.9 million people annually resulting in over 11 million deaths worldwide. In addition to the human toll, sepsis has a significant economic impact, with healthcare costs estimated to be in the billions of dollars every year.

Diagnostic Need

Early detection of infection and inflammatory response is key in improving outcomes, especially in sepsis, with every hour delay to treatment increasing the risk of death by 8-10%. Despite this urgency, current diagnostic methods are often time-consuming, expensive, and unavailable at the point-of-need. Septest's rapid tests intend to bridge this gap by providing simple, low-cost solutions that integrate seamlessly into existing healthcare settings.

Antimicrobial Resistance

The overuse of antibiotics in cases of non-bacterial infections has contributed to the rise of antimicrobial resistance (AMR), posing a significant challenge to infection management. This not only puts a strain on healthcare budgets, but also complicates the treatment of conditions like sepsis. Septest aims to tackle AMR by providing healthcare professionals with tools for accurate diagnosis of infections, ensuring antimicrobials are prescribed only when necessary.

Beyond Sepsis

Septest's diagnostic tests are designed to detect a broad range of infection types and monitor inflammatory response. By offering such comprehensive diagnostic capabilities, Septest has the potential to improve patient outcomes across a vast range of diverse conditions, such as COVID, pneumonia, TB, autoimmune diseases and other chronic inflammatory disorders.

Diagnostic Integration

Hospital Settings

Septest's diagnostic tests have been designed to confirm emergency treatment options following initial clinical assessment.

General Practice

Septest's diagnostic solutions are well suited for use in GP practices to rapidly rule out viruses and other types of infection.

Community Setting

All Septest diagnostic tests may be performed by community health care providers such as pharmacists and at local healthcare clinics.

Our Commitment

We are determined to see our technology in the hands of frontline healthcare workers.

Our ultra-accessible point-of-need tests have been specifically designed to reduce barriers to diagnostic access, especially in LMIC's.

By implementing our range of diagnostic solutions, we believe we can reduce delays to diagnosis, saving countless lives around the world.

Contact Us

For partnership opportunities, or to learn more about our revolutionary tests, please contact us using the form below.

There was an error submitting your message. Please try again.

Thank you! We will get back to you as soon as possible.

Sepsis Charity Information

Further information regarding sepsis and available support can be found by visiting the following registered sepsis charities.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Septest's range of tests are currently in development and not yet available.